Paul Robbins

Company: Allogene Therapeutics

Job title: Vice President, Translational Sciences

Seminars:

Advancements in Minimal Residual Disease (MRD) Diagnostics set the Stage for Novel Clinical Trial 2:30 pm

• Overview of the unmet need in early line large B-cell lymphoma (LBCL) patients • MRD status as prognostic indicator of patient outcomes • Novel trial utilizing innovative biomarker for patient selectionRead more

day: Day Two Track B PM